Cargando…
I BET on anti‐FGFR to fight cancer resistance
L. Altucci and R. Benedetti discuss the study by Chua et al (in this issue of EMBO Molecular Medicine), in which co‐targeting of FGFR signaling increases the responses of metastatic uveal melanoma to BET inhibitors. [Image: see text]
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365924/ https://www.ncbi.nlm.nih.gov/pubmed/30610114 http://dx.doi.org/10.15252/emmm.201810116 |